FDA Gives X-Ray-Blocking Cream Its Own Official Device Classification
Published Date: 6/26/2025
Rule
Summary
The FDA is officially classifying the cream used to block X-rays as a Class II device with special safety rules. This change makes it easier and safer for patients to get this innovative cream by lowering regulatory hurdles. The new classification is effective June 26, 2025, and helps companies bring these creams to market faster without extra costs.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Cream classified Class II; access improved
You may get faster access to this X-ray attenuation cream because the FDA officially classified it as Class II with special controls, effective June 26, 2025 (the classification was applicable May 9, 2013). The FDA says this classification reduces regulatory burdens and will enhance patients' access to this innovative device.
Device uses 510(k) pathway (not PMA)
The cream for X-ray attenuation is subject to premarket notification under section 510(k) rather than premarket approval, and the De Novo classification lets this device serve as a predicate for future devices. That means manufacturers can use the less burdensome 510(k) process to bring similar products to market.
Mandatory testing and labeling requirements
Manufacturers must perform specific safety and performance testing (including biocompatibility, sterilization/expiration testing, glove compatibility, attenuation performance, and application testing) and include labeling such as a sterility statement and boxed warning. Labeling must also give attenuation results at 60, 80, 100, and 120 kVp, identify compatible glove types, and include validated instructions for how and how often to apply or reapply the cream.
Use limits: up to 130 kVp; not for primary beam
The cream is intended as a sterile radiation shield for hands during procedures with diagnostic imaging exposure up to 130 kVp; it should be applied to the hand before donning gloves or on a glove followed by a second glove. The device must not be used in or next to the primary X-ray beam and should not replace a Radiographic Procedure Glove for procedures requiring direct exposure.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11781, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Lysosomal Storage Disorder Newborn Screening Test System
The FDA is officially putting the lysosomal storage disorder newborn screening test system into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and effective while speeding up access to new, helpful devices for babies. The new rules took effect on June 26, 2025, making it simpler and less costly for companies to bring these lifesaving tests to hospitals.
Next: 2025-11793, Medical Devices; Hematology and Pathology Devices; Classification of the Fluorescence In Situ Hybridization-Based Detection of Chromosomal Abnormalities From Patients With Hematologic Malignancies
The FDA is officially classifying a special test that spots chromosome problems in blood cancer patients as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the test is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on June 26, 2025, and could save time and money for companies making these tests.